Global CAR T-Cell Therapy Market Size Likely to Grow at a CAGR of 18.1% By 2033

As per the current market research conducted by the CMI Team, the global CAR T-Cell Therapy Market size is expected to record a CAGR of 18.1% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 3,324.6 Million. By 2033, the valuation is anticipated to reach USD 14,859.1 Million.

CAR T-Cell Therapy Market: Growth Factors and Dynamics

• Advancements in Immunotherapy: The emergence of CAR T-cell therapy represents a significant advancement in cancer treatment, leveraging the body’s immune system to target and eliminate cancer cells. This innovative approach has shown promising results in treating hematologic malignancies and certain solid tumors, driving the market growth.

• Increasing Incidence of Cancer: The rising incidence of cancer worldwide, particularly hematologic malignancies such as leukemia and lymphoma, fuels demand for effective treatment options like CAR T-cell therapy. As cancer rates continue to climb, there is a growing need for targeted therapies capable of achieving durable responses and improving patient outcomes.

• Clinical Success and Regulatory Approvals: The clinical success of CAR T-cell therapies in achieving high response rates and durable remissions has led to regulatory approvals for several products. These approvals signal confidence in the safety and efficacy of CAR T-cell therapies, paving the way for their widespread adoption and commercialization in the market.

• Investment and Research Funding: Significant investments from biopharmaceutical companies, academic institutions, and government agencies drive research and development efforts in CAR T-cell therapy. Funding supports the advancement of novel CAR constructs, manufacturing technologies, and combination therapies, expanding the therapeutic potential and applicability of CAR T-cell therapies across different cancer types.

• Technological Innovations in Manufacturing: Technological advancements in cell therapy manufacturing, such as closed-system bioreactors and automated cell processing platforms, enhance the scalability, reproducibility, and cost-effectiveness of CAR T-cell production. Streamlining manufacturing processes accelerates product development timelines, increases treatment accessibility, and drives market growth.

• Market Expansion into Solid Tumors: While CAR T-cell therapy initially focused on hematologic malignancies, ongoing research efforts are exploring its efficacy in treating solid tumors. The potential expansion of CAR T-cell therapy into solid tumor indications represents a significant growth opportunity, broadening the addressable patient population and diversifying the market landscape.

CAR T-Cell Therapy Market: Partnership and Acquisitions

• In 2023, Selecta Biosciences, Inc. merged with Cartesian Therapeutics, Inc., resulting in a combined entity with over $110 million to support the development of Cartesian’s pipeline. This includes advancing Descartes-08, a potential RNA-engineered CAR T-cell therapy for MG, and other RNA cell therapy programs.

• In 2023, Autolus Therapeutics plc disclosed that the abstract for the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia (ALL) has been chosen for an oral presentation at the European Hematology Association (EHA) 2023 Congress.

Report Scope

CAR T-Cell Therapy Market: COVID-19 Analysis

The COVID-19 pandemic has significantly impacted the CAR T-Cell Therapy Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Clinical Trial Disruptions: The COVID-19 pandemic disrupted clinical trials for CAR T-cell therapies, leading to delays in patient enrollment, site closures, and interruptions in treatment administration. These disruptions affected trial timelines and data collection, slowing down the pace of research and development in the CAR T-cell therapy pipeline.

• Supply Chain Disruptions: COVID-19-related supply chain disruptions, including shortages of raw materials, manufacturing delays, and transportation challenges, affected the production and distribution of CAR T-cell therapies. These disruptions impacted treatment availability, leading to potential delays in patient access to life-saving therapies.

• Resumption of Clinical Trials: As COVID-19 vaccination rates increase and healthcare systems stabilize, clinical trials for CAR T-cell therapies are gradually resuming. Enhanced safety protocols, virtual trial monitoring, and decentralized trial designs facilitate the continuation of research activities while ensuring patient safety and data integrity.

• Investment in Manufacturing Capacity: Biopharmaceutical companies are investing in expanding manufacturing capacity for CAR T-cell therapies to meet growing demand and mitigate supply chain risks. Scaling up production facilities, implementing redundancy measures, and diversifying supplier networks enhance resilience and ensure an uninterrupted supply of therapies to patients.

• Telemedicine Adoption: The adoption of telemedicine and virtual care models facilitates patient access to CAR T-cell therapy consultations, follow-up visits, and monitoring. Telehealth platforms enable remote patient management, reducing the need for in-person clinic visits and minimizing potential exposure to infectious diseases like COVID-19.

• Regulatory Flexibility: Regulatory agencies provide flexibility and guidance to expedite the development and approval of CAR T-cell therapies, recognizing their importance in addressing unmet medical needs. Accelerated review pathways, priority review designations, and regulatory harmonization efforts streamline regulatory processes and facilitate timely market access for innovative therapies.

• Patient Education and Awareness: Efforts to educate patients, caregivers, and healthcare providers about the safety, efficacy, and availability of CAR T-cell therapies help rebuild confidence and trust in the treatment. Patient advocacy organizations, educational campaigns, and peer support networks play a crucial role in raising awareness and facilitating informed treatment decisions.

In conclusion, the COVID-19 pandemic has had a mixed impact on the CAR T-Cell Therapy Market, with some challenges and opportunities arising from the pandemic.

List of the prominent players in the CAR T-Cell Therapy Market:

• Novartis AG
• Gilead Sciences Inc. (Kite Pharma)
• Bristol Myers Squibb (Celgene Corporation)
• Johnson & Johnson (Janssen Pharmaceuticals)
• Bluebird Bio Inc.
• Pfizer Inc. (Kite Pharma)
• Cellectis SA
• Sorrento Therapeutics Inc.
• Legend Biotech Corporation
• Fate Therapeutics Inc.
• Precision Biosciences Inc.
• Atara Biotherapeutics Inc.
• TCR2 Therapeutics Inc.
• CARsgen Therapeutics Ltd.
• Allogene Therapeutics Inc.
• Others

The CAR T-Cell Therapy Market is segmented as follows:

By Drug type

• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Brexucabtagene Autoleucel
• Others

By Indication

• Lymphoma
• Acute Lymphocytic Leukemia
• Others

By Target Antigen

• CD19-targeted Therapies
• CD22-targeted Therapies
• BCMA-targeted Therapies
• EGFRvIII-targeted Therapies
• HER2-targeted Therapies
• Mesothelin-targeted Therapies
• Others

By End User

• Academic Medical Centers
• Hospitals
• Outpatient Clinics
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America